PROGRESSION-FREE SURVIVAL AND POSTPROGRESSION SURVIVAL IN PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH FIRST-LINE CHEMOTHERAPY

被引：0
|
作者：
Shitara, K. [1 ]
Matsuo, K. [2 ]
Muro, K. [3 ]
Ohtsu, A. [1 ]
机构：
[1] East Hosp, Natl Canc Ctr, Kashiwa, Chiba, Japan
[2] Aichi Canc Ctr, Res Inst, Nagoya, Aichi 464, Japan
[3] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：232 / 232
页数：1
相关论文
共 50 条
  • [21] Effect of bevacizumab in first-line chemotherapy on progression-free survival in advanced ovarian clear cell carcinoma.
    Tate, Shinichi
    Nishikimi, Kyoko
    Matsuoka, Ayumu
    Shozu, Makio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer
    Garside, Jamie
    Shen, Qin
    Westermayer, Bernd
    van de Ven, Michiel
    Kroep, Sonja
    Chirikov, Viktor
    Juhasz-Boess, Ingolf
    [J]. CLINICAL THERAPEUTICS, 2023, 45 (10) : 983 - 990
  • [23] BEVACIZUMABIN AND FIRST-LINE CHEMOTHERAPY IN THE TREATMENT OF METASTATIC COLORECTAL CANCER: EVALUATION OF CLINICAL EFFICACY AND PROGRESSION-FREE SURVIVAL
    Liang, Jinhao
    Xiang, Chengjiang
    Sun, Ke
    [J]. FARMACIA, 2023, 71 (04) : 747 - 754
  • [24] CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy
    Matsusaka, S.
    Cao, S.
    Hanna, D. L.
    Sunakawa, Y.
    Ueno, M.
    Mizunuma, N.
    Zhang, W.
    Yang, D.
    Ning, Y.
    Stintzing, S.
    Sebio, A.
    Stremitzer, S.
    Yamauchi, S.
    Parekh, A.
    Okazaki, S.
    Berger, M. D.
    El-Khoueiry, R.
    Mendez, A.
    Ichikawa, W.
    Loupakis, F.
    Lenz, H-J
    [J]. PHARMACOGENOMICS JOURNAL, 2017, 17 (06): : 543 - 550
  • [25] CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy
    S Matsusaka
    S Cao
    D L Hanna
    Y Sunakawa
    M Ueno
    N Mizunuma
    W Zhang
    D Yang
    Y Ning
    S Stintzing
    A Sebio
    S Stremitzer
    S Yamauchi
    A Parekh
    S Okazaki
    M D Berger
    R El-Khoueiry
    A Mendez
    W Ichikawa
    F Loupakis
    H-J Lenz
    [J]. The Pharmacogenomics Journal, 2017, 17 : 543 - 550
  • [26] Exposure to Antibiotics May Affect Progression-Free Survival Negatively in NSCLC Patients Receiving First-Line Chemotherapy
    Tian, X.
    Gong, Y.
    Mei, T.
    Yang, X.
    Xu, Y.
    Yu, M.
    Li, Y.
    Zhu, J.
    Huang, M.
    Zhang, Y.
    Peng, F.
    Zhou, L.
    Zhou, X.
    Xue, J.
    Liu, Y.
    Zou, B.
    Wang, Y.
    Lu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S397 - S398
  • [27] Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer
    Galsky, Matt D.
    Krege, Susanne
    Lin, Chia-Chin
    Hahn, Noah M.
    Ecke, Thorsten
    Moshier, Erin L.
    Sonpavde, Guru
    Godbold, James H.
    Oh, William K.
    Bamias, Aristotelis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [28] Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy
    Apurva Singh
    Hannah Horng
    Leonid Roshkovan
    Joanna K. Weeks
    Michelle Hershman
    Peter Noël
    José Marcio Luna
    Eric A. Cohen
    Lauren Pantalone
    Russell T. Shinohara
    Joshua M. Bauml
    Jeffrey C. Thompson
    Charu Aggarwal
    Erica L. Carpenter
    Sharyn I. Katz
    Despina Kontos
    [J]. Scientific Reports, 12 (1)
  • [29] Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy
    Singh, Apurva
    Horng, Hannah
    Roshkovan, Leonid
    Weeks, Joanna K.
    Hershman, Michelle
    Noel, Peter
    Luna, Jose Marcio
    Cohen, Eric A.
    Pantalone, Lauren
    Shinohara, Russell T.
    Bauml, Joshua M.
    Thompson, Jeffrey C.
    Aggarwal, Charu
    Carpenter, Erica L.
    Katz, Sharyn, I
    Kontos, Despina
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01):
  • [30] Relationship between 6-and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy
    Galsky, Matthew D.
    Krege, Susan
    Lin, Chia-Chi
    Hahn, Noah
    Ecke, Thorsten
    Moshier, Erin
    Sonpavde, Guru
    Godbold, James
    Oh, William K.
    Bamias, Aristotle
    [J]. CANCER, 2013, 119 (16) : 3020 - 3026
12345